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Abstract: Fucan is a term used to denominate a family of sulfated polysaccharides rich in 
sulfated L-fucose. Heterofucan SF-1.5v was extracted from the brown seaweed Sargassum 
filipendula  by  proteolytic  digestion  followed  by  sequential  acetone  precipitation.  This 
fucan  showed  antiproliferative  activity  on  Hela  cells  and  induced  apoptosis.  However,  
SF-1.5v was not able to activate caspases. Moreover, SF-1.5v induced glycogen synthase 
kinase  (GSK)  activation,  but  this  protein  is  not  involved  in  the  heterofucan  SF-1.5v 
induced apoptosis mechanism. In addition, ERK, p38, p53, pAKT and NFκB were not 
affected by the presence of SF-1.5v. We determined that SF-1.5v induces apoptosis in 
HeLa mainly by mitochondrial release of apoptosis-inducing factor (AIF) into cytosol. In 
addition, SF-1.5v decreases the expression of anti-apoptotic protein Bcl-2 and increased 
expression of apoptogenic protein Bax. These results are significant in that they provide a 
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mechanistic  framework  for  further  exploring  the  use  of  SF-1.5v  as  a  novel 
chemotherapeutics against human cervical cancer. 
Keywords: fucoidan; sulfated polysaccharides; anticancer; apoptosis-inducing factor (AIF) 
 
1. Introduction 
Carcinoma of the uterine cervix is the second most common female tumor worldwide, surpassed 
only by breast cancer and its incidence is disproportionately high (>80%) in the developing world. 
Primary treatment can be either surgery or a combination of radiotherapy/chemotherapy for early-stage 
patients.  Treatment  of  distant  disease  is  usually  palliative,  aimed  at  symptom  control.  Targeted 
radiotherapy  may  be  useful  for  controlling  local  symptoms.  While  chemotherapy  may  sometimes 
shrink tumor masses, there is no survival advantage [1]. Better and more effective chemotherapeutics 
are apparently needed for these patients to improve survival rates. 
Evidence has accumulated in recent years, showing that many cancer chemotherapeutic agents kill 
cancer cells by inducing cell death. Cells die in a process that is reversible until a first irreversible 
phase or ‘point-of-no-return’ is reached, but this is not a clearly defined biochemical event [2]. Thus, 
identifying the mode of cell death is recognized as a novel strategy for screening anticancer drugs. As 
a  very  valuable  source  for  novel  chemotherapeutic  reagents,  active  sulfated  homo-heterofucans 
isolated  from  the  brown  seaweed  have  shown  effective  antitumor  activities  with  a  wide  range  of 
mechanisms [3]. 
Fucan is a term used to define a family of L-fucose-containing sulfated polysaccharides found in 
brown seaweed and several species of echinoderms, mostly from the egg jelly of sea urchins [4]. The 
structures of these fucans vary among species and sometimes among different parts of the seaweed [5]. 
Furthermore, in contrast to animal fucans, algal fucans may have portions of other neutral sugars and 
uronic acids in addition to sulfate and fucose in their structures. Some algal fucans exhibit important 
pharmacological  activities  such  as  anticoagulant  [6],  antipeptic  [7],  anticomplementary, 
antiinflammatory,  antiviral  [3],  antiadhesive  [8],  antiproliferative  [9],  antioxidant  [10]  and  
apoptosis-inducing [11,12]. As a result, fucans have a multitude of potential applications in human 
health care. Additionally, biomaterials derived from seaweed generally have an advantage in that there 
is  no  potential  risk  of  contamination  from  animal  viruses  and  bovine  spongiform  encephalopathy 
(BSE) pathogens [13]. 
In a program aimed at determining the bioactivity of sulfated polysaccharides from tropical brown 
seaweeds, we found that the polysaccharide-rich extract from Sargassum filipendula C.Agardh showed 
significant antiproliferative effect on HeLa cell (human uterine adenocarcinoma cell line) proliferation 
[10]. In the preceding article a bioassay-guided fractionation of this extract led to the isolation of an 
antioxidant heterofucan denominated SF-1.5v, which exhibits antiproliferative activity against HeLa 
cells. However, the molecular mechanism underlying the SF-1.5v-induced antiproliferative process 
remains unclear. 
The  primary  objective  of  this  study  was  to  determine  the  relevant  mechanisms  for  an 
antiproliferative effect of the heterofucan SF1.5v. We determined that SF-1.5v induces apoptosis in Mar. Drugs 2011, 9                                                
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HeLa mainly by releasing the apoptosis-inducing factor (AIF) from mitochondria into cytosol. These 
results are significant in that they provide a mechanistic framework for further exploring the use of  
SF-1.5v as a novel chemotherapeutics for human cervical cancer. 
2. Results and Discussion 
2.1. Growth Inhibition by Heterofucan SF-1.5v 
We  studied  the  inhibitory  effect  of  heterofucan  SF-1.5v  (from  0.1  to  2.0  mg/mL)  on  the 
proliferation of HeLa cells cultured for 24, 48 and 72 hours. Figure 1 displays MTT assay results as a 
measure  of  cell  growth.  Proliferation  is  presented  as  a  percentage  of  cell  proliferation  under  no 
treatment  conditions.  A  significant  time  and  dose  dependent  decrease  in  cell  proliferation  was 
observed.  The  effect  was  significant  at  24  hours,  but  optimized  at  72  hours  (Figure  1),  showing 
antiproliferative activity between 32.7% and 72.5% at concentrations from 0.1 to 2.0 mg/mL. 
Figure  1.  HeLa  cell  proliferation  in  the  presence  of  sulfated  polysaccharide  from 
Sargassum filipendula. Each value is the mean ±  SD of seven determinations. 
a,b,c Indicate 
a significant difference (p < 0.05) between treatments at the same concentration. 
 
Antiproliferative activity of the heterofucan SF-1.5v was considerably higher than that of fucans 
from  Sargassum  kjellmanianum  and  Sargassum  stenophyllum,  which  showed  no  more  than  40% 
inhibition activity  on the growth of  L-1210 leukemia  and HeLa  cells, respectively  [14,15].  These 
considerable  variations  in  antiproliferative  activity  between  fucans  likely  result  from  the  various 
chemical  compositions  of  fucan  polymers  originating  in  the  different  species,  anatomical  regions, 
growing conditions of brown seaweeds, extraction and purification procedures as well as the use of 
different cancer cell lines. Mar. Drugs 2011, 9                                                
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2.2. Heterofucan SF-1.5v-Induced Apoptosis in HeLa Cells 
A typical assay was performed to characterize whether cell death resulting from fucan treatment 
was  caused  by  apoptosis  induction.  Thus,  we  examined  the  effect  of  the  fucan  (1.5  mg/mL)  on 
apoptosis using annexin V/PI double staining. One of the early features of cells undergoing apoptosis 
is phosphatidylserine (PS) translocation from the inner to the outer leaflet of the plasma membrane. 
Figure 2 shows PI vs. annexin V-FITC fluorescence. The lower right quadrants represent the early 
apoptotic cells: annexin V binding and PI negative. Annexin V and PI staining revealed that SF-1.5v 
increased apoptosis compared to the control. 
Figure 2. Flow cytometry analysis of apoptotic death of HeLa cells by SF-1.5v. Dot plots 
display  the  apoptotic  death  of  HeLa  cells  treated  with  1.5  mg/ml  of  SF-1.5v.  
Annexin-/PI-  (LL),  viable  cells;  Annexin+/PI-  (LR),  cells  undergoing  apoptosis; 
Annexin+/PI+  (UR),  cells  that  are  in  end-stage  apoptosis  or  are  already  dead. 
LL, lower left;  LR,  lower  right;  UR,  Upper  right.  One  representative  FACS  assay  of 
three independent  experiments  is  presented.  The  percentage  in  LR  corresponds  to  
Annexin+/PI- cells. 
 
2.3. Heterofucan SF-1.5v Treatment-Induced Apoptosis Did Not Require Activation of Caspases in 
HeLa Cells 
As  the  family  of  aspartate-specific  cysteinyl  proteases  (caspases)  plays  a  pivotal  role  in  the 
execution  of  programmed  cell  death,  we  determined  whether  the  apostosis  induction  by  the 
heterofucan  SF-1.5v  resulted  in  activation  of  caspase-9  and  caspase-3.  Caspase  activations  were 
measured  using  western  blot  analysis.  Cells  received  no  treatment  (control)  or  were  treated  with 
heterofucan  SF-1.5v  (1.5  mg/mL)  for  24  hours.  In  response  to  the  heterofucan,  the  activation  of  
pro-caspase-9 and pro-caspase-3 did not increase (Figure 3A). In order to rule out caspase participation Mar. Drugs 2011, 9                                                
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in SF-1.5v-induced apoptosis, the cells were incubated with SF-1.5v (from 0.1 to 2.0 mg/mL) in the 
presence of pan-caspase inhibitor z-VAD (50 mM) for 24 hours. In every condition this compound 
failed  to  inhibit  SF-1.5v-induced  apoptosis  (Figure  3B),  indicating  that  caspase  activation  is  not 
essential for heterofucan SF-1.5v-induced apoptosis in HeLa cells. 
Figure  3.  Heterofucan  SF-1.5v  treatment-induced  apoptosis  did  not  require  caspase 
activation in HeLa cells. (A) Effects of SF-1.5v in activation of upstream caspase-9 and of 
downstream caspase-3. One representative immunoblot of three independent experiments 
is presented. (B) Caspase inhibitor z-VAD (50mM) does not suppress SF-1.5v-induced 
apoptosis in HeLa cells. Each value is the mean ±  SD of seven determinations. 
 
 
 
 
 
 
 
 
Although several studies show fucans inducing cell death by caspase activation, it is known that this 
does not necessarily lead to apoptosis and that caspase inhibition does not necessarily prevent cell 
death, suggesting that caspase blockade or inactivation is not always a useful therapeutic target [2]. 
Additionally, some articles show fucans inducing death by mechanisms independent of caspases. For 
example, Aisa and colleagues [12] showed a fucan from Fucus vesiculosus inducing human lymphoma 
HS-Sultan cell death through activation of ERK pathways. Hyun and colleagues provide evidence 
demonstrating that the pro-apoptotic effect of this fucan from F. vesiculosus is mediated through ERK 
and p38 activation , and blocking of the PI3K/Akt signal pathway in HCT-15 colon carcinoma cells 
[16]. Moreover, F. vesiculosus fucan also affects the NFB pathway [17]. Overall, fucans inhibit cell 
proliferation by affecting different survival pathways depending on cell type. Thus, HeLa cells were 
treated with heterofucan SF-1.5v (1.5 mg/mL) for 24 hours, after we investigated whether heterofucan 
SF-1.5v affects NFB, Akt-GSK-3 and MAPK (ERK and p38) pathways by western blot. 
The heterofucan SF-1.5v did not affect phophorylation of ERK, p38 and NFB proteins. On the 
other  hand,  SF-1.5v  induces  dephosphorylation  (activation)  of  glycogen  synthase  kinase-beta  
(GSK-3)  (Figure  4).  Since  GSK  is  involved  in  activation  of  p53  [18],  we  also  evaluated  the 
phosphorylation  of  this  protein.  However,  it  was  not  affected  by  SF-1.5v  (Figure  4).  GSK 
Dephosphorylation is involved in apoptosis [19], indicating that SF-1.5v likely induces cell death, 
mainly by GSK activation. 
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Figure 4. Analyses of the intracellular signaling of SF-1.5v by western blot. HeLa cells 
were treated with 1.5 mg/mL SF-1.5v for 24 hr. Phosphorylation of ERK, p38, p53, NFB, 
Akt,  and  GSK  was  analyzed  using  phosphospecific  antibodies.  Each  membrane  was  
re-probed with anti-ERK, p38, p53, NFB, Akt, and GSK antibodies to confirm equal 
protein  loading.  One  representative  immunoblot  of  three  independent  experiments  
is presented. 
 
2.4. Heterofucan SF-1.5v Treatment-Induced Apoptosis in the Presence of GSK Inhibitor 
In order to determine the role of GSK in SF-1.5v-induced apoptosis, HeLa cells were incubated 
with  lithium  chloride  (10mM),  a  GSK-specific  inhibitor.  This  was  followed  by  stimulation  with  
1.5 mg/mL SF-1.5v for 24 hours and FACS analysis (Figure 5). Lithium chloride failed to inhibit 
heterofucan SF-1.5v-induced apoptosis, indicating that GSK activation is not essential for apoptosis by 
SF-1.5v in HeLa cells. This result is consistent with that shown by Aisa and colleages. These authors 
showed that the fucan from F. vesiculosus promotes GSK dephosphorylation, but that this effect is not 
involved in fucan-induced death of human HS-sultan cells [12]. 
Figure 5. GSK inhibition by lithium chloride. HeLa cells were pretreated with or without 
10 mM of GSK-specific inhibitor lithium chloride (LiCl), for 1 hr followed by incubation 
with 1.5 mg/mL of fucoidan for 24 hr. Apoptosis detection by annexin-V/PI staining was 
performed,  as  shown  in  Figure  1.  Similar  results  were  obtained  in  three  independent 
experiments. The percentage presented corresponds to Annexin+/PI- cells. 
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2.5. Heterofucan SF-1.5v Induces High Levels of Apoptosis-Inducing Factor (AIF) in Cytoplasm 
Several  studies  have  shown  that  cell  death  is  a  caspase-independent  self-destruction  process 
activated by the mitochondrial pathway, an alternative programmed cell death pathway that occurs in 
the absence of caspase activation [2]. Permeabilization of the organelle that leads to the release of 
several proteins from the intermembrane space involved in organized cell death takes place in the 
mitochondrial pathway. The apoptosis-inducing factor (AIF), one of the soluble factors released from 
mitochondria, is able to force isolated nuclei to adopt apoptotic morphology in a caspase independent 
manner [20]. AIF is an FAD-containing, NADH-dependent oxidoreductase found in the mitochondrial 
intermembrane  space.  It  induces  phosphatidylserine  exposure  on  the  cell  surface.  It  might  also 
maintain apoptogenic ability in the presence of the pan-caspase inhibitor [21]. Given that heterofucan 
SF-1.5v induced phosphatidylserine exposure on the cell surface and maintained apoptogenic ability in 
the presence of the pan-caspase inhibitor, we analyzed the effect of this fucan on the amount of AIF in 
cytosol using western blotting. Figure 6 shows that AIF levels in cytosol are increased when cells were 
exposed  to  heterofucan  SF-1.5v,  indicating  that  the  main  SF-1.5v  cell  death  mechanism  is  the 
mitochondrial release of AIF into the cytoplasm (Figure 6). 
AIF  is  synthesized  as  a  ~67-kDa  preprotein  with  an  N-terminal  extension  and  imported  into 
mitochondria, where it is processed to the ~62-kDa mature form. Topology analysis revealed that 
mature AIF is a type-I inner membrane protein with the N-terminus exposed to the matrix and the  
C-terminal portion to the intermembrane space. Upon induction of apoptosis, processing of mature AIF 
to  a  ~57-kDa  form  occurred  caspase-independently  in  the  intermembrane  space,  releasing  the 
processed form into the cytoplasm. Bcl-2 inhibited both these events [22]. In addition, the Bcl-2 tends 
to  stabilize  the  barrier  function  of  mitochondrial  membranes,  whereas  proapoptotic  Bax  tend  to 
antagonize such function and permeabilize the  membranes. As Bcl-2 plays  an integral role in the 
release of AIF during cell death, we determined its expression and correspondingly, also Bax in control 
and SF-1.5v-treated whole cell extracts. Western blot analysis clearly showed a suppression of Bcl-2 
expression,  accompanied  by  concomitant  increases  in  Bax,  in  SF-1.5v-treated  cells,  compared  to 
control  cells  (Figure  6).  These  results  further  support  the  ability  of  SF-1.5v  to  activate  the 
mitochondria-dependent apoptotic cascade. 
It is clear that fucans have a cell-dependent antitumor effect, since several articles have shown that 
fucans can inhibit the growth of some tumor cell lines, while not influencing the growth of others [3]. 
Moreover, the same fucan induces cell death in different cell lines by activating different cell-death 
signaling pathways, such as the fucan from F. vesiculosus [12,16]. However, this is the first report 
showing a fucan whose main antiproliferative mechanism is promoting the release of AIF from the 
mitochondria into the cytosol. 
In the present study we showed that heterofucan SF-1.5v induces HeLa cell apoptosis by activating 
a cell-death mitochondrial pathway. It would therefore be interesting to investigate whether SF-1.5v 
can overcome the resistance of drug-refractory tumor cells. Additionally, the capacity of SF-1.5v to 
promote  AIF  release  deserves  further  investigation,  which  might  confirm  SF-1.5v  as  a  potential 
candidate for developing anticancer drugs for the treatment of human cervical cancer. Mar. Drugs 2011, 9                                                
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Figure 6. Analysis on AIF, Bax and Bcl-2 expression in the presence of SF-1.5v. HeLa 
cells were treated with 1.5 mg/mL SF-1.5v for 0, 6, 12, 18 and 24 hr. Levels AIF, Bax and 
Bcl-2 released into the cytosol was analyzed by immunoblotting using anti-AIF, anti-Bax 
or anti-Bcl-2 antibodies, as described in Materials and methods. In the boxes below the 
pictures  there  is  the  actin-adjusted  level  of  AIF,  Bax  and  Bcl-2.  One  representative 
immunoblot of three independent experiments is presented.  
 
3. Experimental Section 
3.1. Materials 
Isopropanol, HCl and Tween 20 were obtained from Merck (Darmstadt, Germany). Deoxycholate, 
NaCl,  EDTA,  Na3VO4,  NaF  and  protease  inhibitors  were  purchased  from  Sigma-Aldrich  Co.  
(St. Louis, USA). Cell culture medium components (Dulbecco's Modified Eagle Medium-DMEM), 
trypsin  and  fetal  calf  serum  (FCS)  were  obtained  from  Cultilab  (Campinas,  Brazil).  L-glutamine, 
sodium  bicarbonate,  sodium  pyruvate  and  phosphate  buffered  saline  (PBS)  were  purchased  from 
Invitrogen Corporation (Burlington, ON, USA). All antibodies were purchased from Cell Signaling 
Technology  (Danvers,  MA,  USA).  The  heterofucan  SF-1.5v  was  obtained  as  described  in  the 
preceding article. All other solvents and chemicals were of analytical grade.  
3.2. HeLa Cell Culture 
HeLa cells were obtained from American Type Culture Collection (Manassas, VA, USA). HeLa 
cells were grown as previously described by Almeida-Lima et al. [23]. Briefly, HeLa cells were grown 
in  DMEM  medium  supplemented  with  10%  fetal  calf  serum  (FCS)  (1%  penicillin/streptomycin  
(10000 U/mL penicillin G sodium, 10000 mg/mL streptomycin sulfate). Cells were grown at 37 ° C in 
a humidified 5% CO2 incubator. HeLa cells were seeded at a density of 5 ×  10
6 for 75 cm
3 flasks. Mar. Drugs 2011, 9                                                
 
 
611 
3.3. Antiproliferative Activity 
Antiproliferative activity of SF-1.5v was determined as previously described by Amoli et al. [24]. 
Briefly, HeLa cells were grown in 75 cm
3 flasks in DMEM medium plus 10% FCS. Cells were seeded 
into 96-well plates at a density of 5 ×  10
3 cells/well and allowed to attach overnight in 300 μL medium 
FCS free incubated at 37 º C, 5% CO2. The medium was then removed and 300 μL of medium/ plus 
FCS was added, followed by heterofucan SF-1.5v at a final concentration of 0.1; 0.5; 1.0; 1.5 and  
2.0 mg/mL. Cells growing under these conditions for 24 h, 48 h and 72 h at 37 ºC  at 5% CO2. After 
incubation, traces of SF-1.5v were removed by washing the cells twice with 200 μL PBS and applying 
100 μL of fresh medium and 10 μL of 12 mM MTT dissolved in PBS to determine the effects of the 
heterofucan on cell proliferation. Cells were then incubated for 4 h at 37 º C, 5% CO2. To solubilize the 
product of MTT cleavage, 100 μL of isopropanol containing 0.04 N HCl was added to each well and 
thoroughly mixed using a multichannel pipettor. Within 1 h of HCl-isopropanol addition, absorbance 
at 570 nm was read using a Multiskan Ascent Microplate Reader (Thermo Labsystems, Franklin, MA, 
USA). The percent inhibition of cell proliferation was calculated as follows: 
% Inhibition = Abs. 570 nm Control − Abs. 570 nm sample 
×  100 
Abs. 570 nm Control 
3.4. Apoptosis Assay 
The apoptotic status of HeLa cells was evaluated by measuring the exposure of phosphatidylserine 
on  cell  membranes  using  annexin  V-fluorescein  isothiocyanate  (annexin  V-FITC)  and  propidium 
iodide (PI) staining. A BD Pharmingen Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, 
Franklin  Lakes, NJ) was used for the apoptosis assay. HeLa cells were placed in a 24-well plate  
(1 ×  106 cells/mL), and after 24 h of incubation, cells were treated with SF-1.5v for 24h and then 
harvested. After centrifugation, cell pellets were washed twice with cold phosphate-buffered saline 
(PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, pH 7.4) and suspended in 100 μL of 1 ×  binding 
buffer (10 mM HEPES/NaOH, 140 m M NaCl, 2.5 mM CaCl2, pH 7.4). Cells were then incubated 
with 5 μL of annexin V-FITC and 10 μL of PI at room temperature for 15 min in the dark. After 
incubation, 400 μL of 1 ×  binding buffer was added to each tube. The cells were immediately analyzed 
by FACSCalibur flow cytometry (Becton Dickinson, USA). 
3.5. Western Blotting 
HeLa cells at 80% confluence were incubated with SF-1.5v and washed after 24 h in ice-cold PBS 
and  scraped  into  200  mL  lysis  buffer  [50  mM  Tris-HCl  (pH  7.4),  1%  Tween  20,  0.25%  sodium 
deoxycholate,  150 mM  NaCl, 1 mM EDTA, 1 mM Na3VO4, 1  mM NaF,  and protease inhibitors  
(1 mg/mL aprotinin, 10 mg/mL leupeptin and 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride] for  
2 h in ice. Protein extracts were cleared by centrifugation and protein concentrations were determined 
using BCA protein assay kit (Pierce, USA) with bovine serum albumin as standard. An equal volume 
of  sodium  dodecyl  sulfate  (SDS)  gel  loading  buffer  [100  mM  Tris-HCl  (pH  6.8),  200  mM 
dithiothreitol (DTT), 4% SDS, 0.1% bromophenol blue and 20% glycerol] was added to samples, Mar. Drugs 2011, 9                                                
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which were subsequently boiled for 10 min. From each sample, 50 mg of protein was loaded onto 
SDS-PAGE and blotted onto PVDF membranes (Millipore, Bedford, MA, USA). Membranes were 
blocked in 1% fat-free dried milk or 2% bovine serum albumin in Tris-buffered saline (TBS) with 
0.05%  Tween  20  (TBST)  and  incubated  overnight  at  4  ° C  with  appropriate  primary  antibody  at  
1:1000  dilution.  After  washing  in  TBST,  membranes  were  incubated  with  anti-rabbit  horseradish 
peroxidase-conjugated  secondary  antibodies,  at  1:2000  dilution;  in  blocking  buffer  for  1  h.  The 
intensity of the specific immunoreactive bands were detected by enhanced chemiluminescence (ECL), 
using the manufacturer's protocol (Kirkegared and Perry Laboratories) and quantified by densitometry 
and expressed as a ratio to actin, as previously described [22]. 
3.6. Statistical Analysis 
All data were expressed as mean ±  standard deviation. Statistical analysis was done by one-way 
Anova using the SIGMAStat 2.01 software. Student-Newmans-Keuls post-tests were performed for 
multiple group comparison. In all cases statistical significance was set at p < 0.05. 
4. Conclusions 
Our  studies  demonstrate  that  heterofucan  SF-1.5v  inhibited  growth  of  the  Hela  human  uterine 
adenocarcinoma cell line by inducing apoptosis using a mechanism independent of caspases activation. 
SF-1.5v  also  induces  GSK  activation,  but  this  protein  is  not  involved  in  the  heterofucan  
SF-1.5v-induced apoptosis mechanism. SF-1.5v induces apoptosis mainly by inducing AIF release 
from mitochondria into cytosol. These data support the hypothesis that SF-1.5v may have potential for 
treating cervical cancer. 
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